Here are three insights:
1. The Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety Risk Management Advisory Committee approved the two drugs.
2. The panel voted 14 to 3 on Vantrela, and 9 to 6 on Troxyca.
3. Vantrela is an abuse-deterrent formulation of extended-release hydrocodone. Troxyca is an abuse-deterrent formulation of extended-release oxycodone with naltrexone.
More articles on quality & infection control:
NY legislation exempts drugstores from some patient safety standards: 5 things to know
Top 10 states with the highest & lowest ASC patient burn rates
FDA eases paperwork burden for experimental drugs — 5 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
